Higher Red Cell Distribution Width to Albumin Ratio (RAR) associated with increased mortality in pulmonary sepsis
High RAR linked to higher death risk in pulmonary sepsis patients
A retrospective dual-cohort study of 6,065 patients with pulmonary sepsis found that a higher Red Cell Distribution Width to Albumin Ratio (…
A high Red Cell Distribution Width to Albumin Ratio score predicts a significantly greater chance of dying within 28 days for patients with …
Retrospective study links IVIG plus azithromycin to higher response rate in pediatric Mycoplasma pneumoniae pneumonia
When a Child's Pneumonia Won't Clear, This Add-On May Help
A single-center retrospective cohort of 140 children with Mycoplasma pneumoniae pneumonia found that adding intravenous immunoglobulin (IVIG…
Adding donor antibodies to standard antibiotics helped 97% of children with stubborn pneumonia recover, compared to 84% on antibiotics alone…
In vitro amikacin resistance linked to kanamycin cross-resistance but not streptomycin in M. avium-intracellulare complex
Lost to Amikacin? Streptomycin Might Still Work
This single-center retrospective study evaluated cross-resistance among aminoglycosides in 20 patients with amikacin-resistant M.
When amikacin fails to treat stubborn lung infections, streptomycin often remains effective, offering hope for patients facing drug-resistan…
Daily Vitamin D increased HDAC2 and 25(OH)D levels in stable COPD patients without improving pulmonary function
Vitamin D supplement increased a protein marker in five COPD patients
This experimental study evaluated the effect of daily 5000 IU Vitamin D in five stable COPD patients over three months.
Daily Vitamin D supplements raised a protein marker in five COPD patients, but the study found no significant improvement in lung function a…
Low-dose theophylline shows modest FEV improvement but no exacerbation reduction in mild to moderate COPD
Can a low-dose pill help people with mild COPD breathe easier?
A 12-month randomized trial in 734 Chinese patients with mild to moderate COPD found oral low-dose theophylline (100 mg twice daily) produce…
A low-dose theophylline pill helped mild COPD patients exhale slightly better but did not reduce dangerous flare-ups during a year-long stud…
Genetic analysis links oral microbiota to COPD risk in East Asian population
Could the bacteria in your mouth affect your risk of COPD?
A genetic causal inference and bioinformatics analysis using East Asian GWAS data identified 48 oral microbial taxa associated with COPD ris…
A study in East Asian people links 48 types of mouth bacteria to COPD risk and identifies a gene and six existing drugs that might target it…
Prolonged prone positioning shows oxygenation benefit but inconclusive mortality effect in COVID-19 ARDS
Longer prone positioning may improve oxygen levels in COVID-19 ARDS patients
A meta-analysis of 996 COVID-19 patients with moderate-to-severe ARDS compared prolonged (>24 h/session) to standard (≤24 h/session) prone p…
Prolonged prone positioning for severe lung failure showed a trend toward lower death rates but increased pressure injury risks in COVID-19 …
SBRT shows early QoL advantage over CHRT in inoperable stage I NSCLC, but long-term scores converge
Which radiation therapy helps people with inoperable lung cancer feel better?
A phase 3 RCT of 233 patients with medically inoperable stage I NSCLC compared SBRT to CHRT.
For inoperable lung cancer, a newer radiation method offers early relief but conventional therapy catches up in overall health by two years.
FDA Approves Nintedanib Capsules (nintedanib esylate) for Idiopathic Pulmonary Fibrosis and Progressive Fibrosing ILDs
FDA approves a new drug to treat two serious, scarring lung diseases in adults
The FDA has approved nintedanib capsules for the treatment of adults with idiopathic pulmonary fibrosis (IPF) and for adults with chronic fi…
FDA approves new drug nintedanib to treat two serious, scarring lung diseases in adults with progressive conditions.
FDA Approves Nintedanib Capsules (nintedanib esylate) for Idiopathic Pulmonary Fibrosis and Progressive Fibrosing ILDs
FDA approves a new drug to treat two types of progressive, scarring lung diseases
The FDA has approved nintedanib capsules for the treatment of adults with idiopathic pulmonary fibrosis (IPF) and for adults with chronic fi…
FDA approves new drug to treat two types of progressive, scarring lung diseases that make lungs stiff and hard to breathe.
Durvalumab plus chemotherapy shows 35% response in phase II trial for metastatic pulmonary sarcomatoid carcinoma
Small study tests drug combination for rare, aggressive lung cancer
A phase II single-arm trial in 20 patients with recurrent/metastatic pulmonary sarcomatoid carcinoma evaluated durvalumab plus doxorubicin/i…
A rare lung cancer drug combo shrank tumors in 35% of patients, offering hope for those with this aggressive disease despite common side eff…
BACE plus tislelizumab shows activity in advanced NSCLC patients ineligible for standard care
Combination treatment shows promise for advanced lung cancer patients ineligible for standard care
A Phase II, single-arm trial in 30 patients with Stage IIIA-IIIC NSCLC who refused or were ineligible for standard treatment evaluated bronc…
A new combo treatment for advanced lung cancer patients ineligible for standard care helped 60% shrink tumors and extended survival to 15 mo…